Background: ROR␥t is the master transcription factor in Th17 cells. Results: USP17 stabilizes ROR␥t via deubiquitination, and USP17 levels are up-regulated in systemic lupus erythematosus. Conclusion: USP17 is a positive regulator of ROR␥t. Significance: USP17 could be a potential drug target to modulate ROR␥t-mediated autoimmune diseases such as systemic lupus erythematosus.
Stable retinoic acid-related orphan nuclear receptor ␥t (ROR␥t) expression is pivotal for the development and function of Th17 cells. Here we demonstrate that expression of the transcription factor ROR␥t can be regulated through deubiquitination, which prevents proteasome-mediated degradation. We establish that USP17 stabilizes ROR␥t protein expression by reducing ROR␥t polyubiquitination at its Lys-360 residue. In contrast, knockdown of endogenous USP17 in Th17 cells resulted in decreased ROR␥t protein levels and down-regulation of Th17-related genes. Furthermore, USP17 expression was up-regulated in CD4 ؉ T cells from systemic lupus erythematosus patients. Our data reveal a molecular mechanism in which ROR␥t expression in Th17 cells can be positively regulated by USP17, thereby modulating Th17 cell functions.
Th17 cells are characterized as a distinct subset of CD4 ϩ T cells that play an important role in the immune responses against fungi and bacteria (1, 2) . Th17 cells mediate proinflammatory functions through the secretion of proinflammatory cytokines, including IL-17A (IL-17), IL-17F, and IL-22 (2) . Moreover, the involvement of Th17 cells has been implicated in the development of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus (3) .
It has been widely recognized that differentiation of the Th17 lineage requires TGF-␤ and IL-6 following T cell antigen stimulation (2) . In addition, IL-1␤ and IL-23 are essential components of human Th17 differentiation and the expression of Th17-related genes (4, 5) . However, not all Th17 cells are pathogenic. In vivo studies by Lee et al. (6) demonstrated that acquisition of the full pathogenic phenotype in Th17 cells is attributed to IL-6 and TGF-␤3 and that the production of TGF-␤ is IL-23-dependent.
Retinoic acid-related orphan nuclear receptor ␥t (ROR␥t) has been identified as the master transcription factor required for the differentiation, maintenance, and proinflammatory functions of Th17 cells (7, 8) . ROR␥t, which is induced by TGF-␤ and IL-6, directs the transcription of the related cytokines IL-17 and IL-17F in primary CD4 ϩ T helper cells. Mice with a T cell-associated ROR␥t genetic deficiency exhibit decreased levels of Th17 cytokines and attenuated disease manifestations in an experimental model of autoimmune encephalomyelitis (7) . So far, several factors have been identified that regulate the expression and activation of ROR␥t. Upstream stimulatory factor 1 (USF1) and USF2 are necessary for ROR␥t transcription in differentiating Th17 cells (9) . Leptin promotes Th17 responses by inducing ROR␥t transcription both in vitro and in vivo (10) , and AT-rich interactive domain-containing protein 5a (ARID5A) interacts with ROR␥t and suppresses its activity, therefore inhibiting ROR␥t-induced Th17 cell differentiation (11) . Despite its importance in Th17 function and differentiation, relatively little is known about the enzymes that directly regulate ROR␥t posttranslational modification and protein stability.
Protein ubiquitination is process that attaches ubiquitin to lysine residues on target proteins and is mediated reciprocally by both E3 ubiquitin ligases and deubiquitinating enzymes. This modification regulates a host of intracellular processes, including proteasome proteolysis, protein trafficking, and functional modulation (12, 13) .
So far, many groups have confirmed that the ubiquitination system plays an important role in the differentiation and function of Th17 cells and the IL-17 signaling pathway. PDZ-LIM domain protein (PDLIM2), a nuclear ubiquitin E3 ligase, inhibits TH17 cell-mediated inflammatory responses by suppressing STAT3 signaling (14) . The ubiquitin-specific protease USP25 has been identified as a negative regulator of IL-17-mediated signaling and inflammation through the removal of ubiquitination on TRAF5 and TRAF6 (15) , and USP18 has been found to regulate T cell activation and Th17 cell differentiation by deubiquitinating the TAK1-TAB1 complex (16) . However, the underlying mechanisms that directly regulate the ubiquitination or deubiquitination of ROR␥t remain unclear.
The human genome encodes almost 100 deubiquitinating enzymes (DUBs) 4 for ubiquitination, and these are divided into five families: the ubiquitin C-terminal hydrolases, ubiquitinspecific protease (USP), ovarian tumor, Josephin domain, and JAB1/MPN/Mov34 metalloenzyme domain zinc-dependent metalloprotease families (17) . USP17, also called DUB-3, has been identified as a deubiquitinating enzyme that belongs to a subfamily of cytokine-inducible DUBs. USP17 is induced in response to IL-4 and IL-6 and is ubiquitously expressed in various tissues and cells (18) . USP17 can regulate virus-induced type I IFN signaling through the deubiquitination of RIG-I and melanoma differentiation-associated protein 5 (MDA5) (19) . USP17 modulates the translocation and activation of the GTPase Ras by negatively regulating Ras-converting enzyme 1(RCE1) (20) . Furthermore, USP17 is also indispensable for cell cycle progression and cell migration (21) .
Here we identified USP17 as a deubiquitinase for ROR␥t that promotes Th17 cell functions. We further demonstrated that USP17 decreased the polyubiquitination and inhibited the proteasome-dependent degradation of ROR␥t at its Lys-360 residue, thereby promoting ROR␥t signaling. Consistently, a deficiency in USP17 resulted in decreased ROR␥t protein levels and ROR␥t-mediated activation of genes such as IL-17 and IL-17F. Furthermore, we also demonstrated that USP17 transcriptional levels were up-regulated in systemic lupus erythematosus compared with healthy controls. Therefore, our work identifies a novel positive regulator of ROR␥t that is crucial for Th17 cell functions.
EXPERIMENTAL PROCEDURES
Plasmids and Antibodies-ROR␥t, USP17, and their corresponding truncations were amplified by PCR with human cDNA from HEK293T cells. These fragments were then cloned into pIPHA-tagged, pIPMyc-tagged, or pIPFLAG-tagged vectors. The USP17C89S mutant was constructed with the QuikChange II site-directed mutagenesis kit (Stratagene). The antibodies used in this study were anti-FLAG (catalog no. M2, Sigma), anti-Myc (catalog no. 9E10, Santa Cruz Biotechnology), anti-GAPDH (catalog no. 1C4, Sungene Biotech), anti-␤-actin (catalog no. C1213, Sungene Biotech), anti-ROR␥t (catalog no. sc-28559X, Santa Cruz Biotechnology; catalog no. 14-6988, eBioscience), anti-USP17 (catalog no. sc-103318, Santa Cruz Biotechnology), PerCP/Cy5.5 anti-human CD45RA antibody (catalog no. 304121, Biolegend), FITC anti-human CD4 antibody (catalog no. 300506, Biolegend), and phycoerythrin (PE) anti-human CD25 antibody (catalog no. 302606, Biolegend).
Cell Culture and Transfection-293T cells were cultured in DMEM (Hyclone) supplemented with 10% FBS (catalog no. 131212, ExCell Biology). Jurkat cells were cultured in RPMI 1640 medium (Hyclone) containing 10% FBS (catalog no. GXM0109, Hyclone), 1% sodium pyruvate, 1% non-essential amino acids. Naïve CD4 ϩ T cells and Th17 cells were cultured in X-VIVO 15 medium (catalog no. 04-418Q, Lonza) supplemented with 10% human AB serum (Invitrogen), 1% sodium pyruvate, 1% GlutaMax, 1% non-essential amino acids, and 1% penicillin/streptomycin. Jurkat cells were activated by treatment with phorbol 12-myristate 13-acetate (50 ng/ml) plus ionomycin (1 M). 293T cells were transfected with the appropriate plasmids using PEI reagent (catalog no. 23966, Polysciences), and Jurkat cells were transfected by electroporation (NEPA21) according to the instructions of the manufacturer.
Th17 Induction and Expansion-Naive CD4 ϩ CD45RA ϩ -CD25 Ϫ T cells were purified by FACS. Peripheral blood mononuclear cells were isolated by Ficoll (Life) density gradient centrifugation, and FACS sorting was performed to isolate the lineage: naïve CD4 ϩ T cells (CD4-FITC, CD25-PE, and CD45RA-APC). These cells were stimulated with CD3/CD28 beads (catalog no. 11132D, Invitrogen) in the medium described above. Th17 cells were polarized in the presence of 2.5 ng/ml rhTGF-␤1 (catalog no. 240-B-002, R&D Systems), 50 ng/ml rhIL-6 (catalog no. 206-IL-010, R&D Systems), 10 ng/ml rhIL-1␤ (catalog no. 201-LB-005, R&D Systems), and 100 ng/ml rhIL-23 (catalog no. 1290-IL-010, R&D Systems) for 7 days. Th17 cells were then harvested for a future assay.
Luciferase Reporter Assay-Human genomic DNA was used as a template to produce 0.6-kb fragments of the Il17a promoter according to Ref. 22 . The product was cloned into the pGL4 basic luciferase vector. To analyze the effects of USPs on ROR␥t in terms of Il17a promoter activity, the Il17a luciferase reporter plasmid was cotransfected with a ␤-gal or Renilla luciferase reporters into 293T or Jurkat T cells. After 48 h, the cells were lysed, and luciferase assays were performed using the Dual-Luciferase reporter kit (Promega).
Immunoblotting and Coimmunoprecipitation-Cells were lysed in radioimmune precipitation assay buffer consisting of 20 nM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 10% glycerol, 0.5% sodium deoxycholate, 1 mM PMSF, 1 mM NaF, 1 mM Na 3 VO 4 and 1% protease inhibitor mixture (catalog no. P8340, Sigma). Cell lysates were incubated with appropriate antibodies for 1 h at 4°C and then with protein A/G Plus-agarose for another 1 h at 4°C. Then beads were washed with radioimmune precipitation assay four times and detected by immunoblotting. Protein A/G Plus-agarose (catalog no. sc-2003) was purchased from Santa Cruz Biotechnology.
Ubiquitin Pulldown Assay-293T cells transfected with FLAG-tagged ROR␥t, Myc-USP17, and His-tagged ubiquitin were treated with 20 nM MG132 for 3 h before harvesting. Cells were washed with ice-cold 1ϫ PBS and lysed in urea buffer (10 mM Tris (pH 8.0), 8 M urea, 100 mM Na 2 HPO 4 , 0.2% Triton-100, 1 mM N-ethylmaleimide, and 10 mM imidazole) at pH 8.0 for 30 min. The lysates were incubated with Ni-NTA acid beads (catalog no. 30210, Qiagen) for 3 h at room temperature. The beads were washed three times in urea buffer (pH 8.0) before incubation. After 3 h of incubation, the beads were washed twice in urea buffer (pH 8.0), twice in urea buffer (10 mM Tris (pH 6.3), 8 M urea, 100 mM Na 2 HPO 4 , 0.2% Triton X-100, and 10 mM imidazole) (pH 6.0), and once in a wash buffer (20 mM Tris at pH 8.0, 100 mM NaCl, 20% glycerol, 1 mM dithiothreitol, and 10 mM imidazole). Beads were boiled in 30 l of 2ϫ loading buffer for 5-10 min and separated on an SDS-PAGE gel, and then ubiquitination levels were evaluated by Western blotting with specific antibodies as indicated.
RNA Isolation and RT-PCR-Total RNA was extracted from whole cells as well as CD4 ϩ T cells from systemic lupus erythematosus (SLE) patients and healthy controls (RNeasy micro kit, Qiagen) following the instructions of the manufacturer. RNA concentrations were quantified with a Nanodrop ND-1000 spectrophotometer, and then RNA was reverse-transcribed into complementary DNA (PrimeScript RT reagent kit, TaKaRa). Real-time PCR was performed with SYBR Green mix (SYBR Premix Ex Taq TM , TaKaRa) using the ABI Prism 7500 sequence detection system (Applied Biosystems).
The primers used were as follows: IL-17A, 5Ј-ACCAATCCC-AAAAGGTCCTC-3Ј (forward) and 5Ј-GGGGACAGAGTTCA-TGTGGT-3Ј (reverse); IL-17F, 5Ј-CCTCCCCCTGGAATTAC-ACT-3Ј (forward) and 5Ј-ACCAGCACCTTCTCCAACTG-3Ј (reverse); ROR␥t, 5Ј-CTGCTGAGAAGGACAGGGAG-3Ј (forward) and 5Ј-AGTTCTGCTGACGGGTGC-3Ј (reverse); USP17, 5Ј-GAGCACTTGGTGGAAAGAGC-3Ј (forward) and 5Ј-TGA-TGGTTCTTCATCCCACA-3Ј (reverse); and GAPDH, 5Ј-GAG-TCAACGGATTTGGTCGT-3Ј (forward) and 5Ј-GCCATGGG-TGGAATCATATTGG-3Ј (reverse).
Lentiviral Constructs and Transduction-shRNA sequences were synthesized by Shanghai Sunny Biotechnology Co. Ltd., and the oligos were cloned into the shRNA lentiviral vector PLKO.1. 293T cells were cotransfected with shUSP17, del8.9, and vesicular stomatitis virus G (VSV-G) for lentivirus transduction. Forty-eight hours later, the supernatants containing virus were harvested for future knockdown assays. Th17 cells or Jurkat cells were incubated with viral supernatants containing 8 g/ml of Polybrene overnight. The viral supernatants were replaced with fresh medium on day 2. G418 or puromycin was added to screen the cells 2 days post-transduction for stable cell lines.
The shRNA sequences were as follows: CAACAAGATG-AAGAGCACCAA (shCK), AAGCAGGAAGATGCCCATGAA (shUSP17-1), AAGTCACCACTCTCATGTGAG (shUSP17-3), and GACACAGACAGGCGAGCAACG (shUSP17-3).
CD4 ϩ T Cell Isolation-Human peripheral blood was collected from SLE patients who fulfilled the American College of Rheumatology criteria for the diagnosis of SLE as well as from healthy donors. The patients were between 23 and 56 years old and were recruited from the Rheumatology Department of Huashan Hospital (Shanghai, China). The SLE patients were divided into two groups according to the disease activity index (SLEDAI): an inactive group (SLEDAI Ͻ10) and an active group (SLEDAI Ͼ10). CD4 ϩ T cells were isolated from whole blood using a human CD4 ϩ T cell enrichment mixture (StemCell Technologies). Total RNA was extracted following the same method as that used for RNA isolation.
RESULTS

USP17 Up-regulates the Activation of ROR␥t-dependent
Il17a Promoter Transcriptional Activity-To investigate whether certain ubiquitinases can regulate ROR␥t-mediated transcriptional activity, we constructed 0.6-kb Il17a promoter reporter plasmids to which ROR␥t could bind directly (22) . Subsequently, we screened the effects of DUBs on ROR␥t-mediated transcriptional activities via the cotransfection of 18 DUBs with ROR␥t and luciferase constructs derived from the Il17a promoter into 293T cells. USP17 significantly up-regulated ROR␥t-mediated luciferase activity among the 18 DUBs (Fig.  1A) . Moreover, USP17 increased ROR␥t-mediated Il17a promoter activity, whereas the enzyme-inactive mutant USP17C89S could not (Fig. 1B) . Simultaneously, we constructed stable Jurkat cell lines that expressed ROR␥t (supplemental Fig. S1 ). Similar luciferase experiments were performed in FLAG-ROR␥t-Jurkat cells. A significant dose-dependent effect of USP17 was observed after T cell activation (Fig. 1C) . These results suggest that USP17 operates directly on ROR␥t to enhance ROR␥t-mediated Il17a promoter activation and that the enzymatic activity of USP17 is essential for positive regulation.
USP17 Interacts with ROR␥t-We hypothesized that USP17 may associate with ROR␥t, which contributes to the increased activation of Il17a promoter activity. To validate our hypothesis, Myc-tagged USP17 and FLAG-tagged ROR␥t were cotransfected into 293T cells for a coimmunoprecipitation assay. The results revealed that USP17 could interact with ROR␥t in a reciprocal fashion ( Fig. 2A) . Moreover, we confirmed the endogenous protein interaction between USP17 and ROR␥t in human primary Th17 cells (Fig. 2B ).
ROR␥t comprises an N-terminal DNA-binding domain, a hinge region, and a C-terminal ligand-binding domain (Fig.  2B) . To identify the binding domains utilized by ROR␥t and USP17, we cotransfected Myc-tagged USP17 and FLAGtagged, full-length ROR␥t or a series of truncation mutants (1-248, 75-248, and 248 -497), followed by a coimmunopre-cipitation assay. The results indicated that both the N-terminal DNA-binding and C-terminal ligand-binding domains of ROR␥t could interact with USP17 (Fig. 2C) . These data suggest that the DNA-binding and ligand-binding domains of ROR␥t are required for its interaction with USP17.
USP17 Stabilizes and Deubiquitinates ROR␥t-Because USP17 interacts with ROR␥t, and because the enzymatic activity of USP17 is essential for promoting ROR␥t-mediated activation of the Il17a gene promoter, we speculated that USP17 might affect ROR␥t stability. 293T cells were introduced with FLAG-tagged ROR␥t, Myc-tagged USP17, or a controlled FLAG vector, and the protein levels were determined by Western blotting. We found that USP17 stabilized ROR␥t in a dose-dependent manner (Fig. 3A) . To further validate this conclusion, we detected ectopically expressed ROR␥t pro-tein levels with or without USP17 or USP17C89S in the presence of the protein synthesis inhibitor cycloheximide at the indicated time points by Western blotting. Consistently, the overexpression of USP17, but not its enzyme-inactive mutant, had prominent effects on the stability of the ROR␥t protein (Fig. 3, B and C) .
We then sought to identify whether USP17 activity depends on its deubiquitinating enzymatic activity. We first confirmed that ROR␥t could be ubiquitinated in 293T cells, which were cotransfected with Myc-ROR␥t and FLAG-ubiquitin, followed by coimmunoprecipitation with an anti-Myc antibody (Fig.  4A ). To verify our hypothesis, we cotransfected FLAG-tagged ROR␥t with His-ubiquitin and USP17 or USP17C89S into 293T cells, and His-tagged proteins were then recovered on Ni-NTA beads under denaturing conditions. As expected, wild-type FIGURE 1. USP17 up-regulates ROR␥t-mediated Il17a promoter transcriptional activity. A, the effects of DUB family members with ROR␥t on Il17a promoter activity. The Il17a luciferase reporter and a control ␤-gal luciferase reporter were cotransfected into 293T cells with the indicated 18 plasmids. Forty-eight hours later, cells were harvested, and luciferase activity was detected. B, FLAG-tagged ROR␥t and increasing amounts of USP17 (1 and 2 g) or its mutant, USP17C89S, were cotransfected into 293T cells with the Il17a luciferase reporter. Forty-eight hours after transfection, cells were lysed, and luciferase activity was measured. NS, not significant. C, Myc-USP17 (3 and 6 g) and the Il17a luciferase reporter were transfected into FLAG-ROR␥t-Jurkat cells by electroporation. Forty-eight hours after transfection, cells were stimulated by 12-myristate 13-acetate (PMA) and ionomycin for 12 h and then lysed for the luciferase assay. DMSO, dimethyl sulfoxide. Data are representative of more than three independent experiments, and error bars show mean Ϯ S.D. USP17, but not the USP17CS mutant, reduced the polyubiquitination of ROR␥t (Fig. 4B) .
Because of the presence of seven lysine residues (Lys-6, Lys-11, Lys-27, Lys-29, Lys-33, Lys-48, and Lys-63) in ubiquitin, ubiquitin molecules can form different types of polyubiquitin chains with distinct functions. Ubiquitination via Lys-48 linkage or Lys-63 linkage is currently best characterized. Lys-48linked polyubiquitin chains have been shown to result in the proteasomal degradation of modified proteins, whereas Lys-63linked chains represented several non-proteolytic signals in SEPTEMBER 12, 2014 • VOLUME 289 • NUMBER 37 JOURNAL OF BIOLOGICAL CHEMISTRY 25551 several intracellular pathways (13) . To identify which lysine residue was required for ROR␥t deubiquitination by USP17, we performed denaturing Ni-NTA purification by coexpressing ROR␥t with ubiquitin mutants (Lys-48only and Lys-63only). ROR␥t was more heavily deubiquitinated in the presence of USP17 with the Lys-48only mutant (Fig. 4C) . Taken together, these results establish the mechanism by which USP17 promotes increased ROR␥t protein levels, which is that USP17 stabilizes ROR␥t through Lys-48-linked deubiquitination, which prevents ROR␥t degradation.
Identification of USP17 as a Positive Regulator of ROR␥t
USP17 Deubiquitinates ROR␥t Mainly at Lysine 360 of ROR␥t-To examine the specific site of deubiquitination of ROR␥t by USP17, we first confirmed that ROR␥t had multiubiquitinating sites by cotransfection with FLAG-ROR␥t and the ubiquitin mutant Lys-0 (all lysine residues were mutated to arginine) into 293T cells (Fig. 5A ). We performed further experiments to show that USP17 could significantly deubiquitinate the ligand-binding domain (amino acids 248 -497) of ROR␥t with multi-, poly-, and/or monoubiquitinating sites (Fig. 5B ). Then we screened the lysine mutants of the ligandbinding domain and identified lysine 360 as a potential deubiquitinating site by USP17 (Fig. 5, C and D) . A point mutation of ROR␥t at lysine 360 into arginine (K360R mutant) could abolish USP17-mediated stabilization and accumulation of ROR␥t, whereas the other simultaneous mutations within this ligand-binding domain could not (Fig. 5C ). Furthermore, the ROR␥t-K360R mutant partly abrogated the deubiquitination effect of USP17 on ubiquitinated ROR␥t (Fig. 5D ). A, His-tagged wild-type ubiquitin (Ubi) and its mutant, Lys-0 (K0), were cotransfected with FLAG-tagged ROR␥t to detect the ubiquitination of ROR␥t. The ubiquitin pulldown assay was performed as described under "Experimental Procedures." IB, immunoblot. B, FLAG-tagged wild-type ROR␥t, its truncation mutants, Myc-tagged USP17, and His-tagged ubiquitin. The ubiquitin pulldown assay for FLAG-tagged ROR␥t was performed as described under "Experimental Procedures." aa, amino acids. C, all point mutants of ROR␥t were cotransfected with FLAG-tagged USP17 into 293T cells. After 48 h, cells were lysed and immunoblotted with the indicated antibodies. D, 293T cells were transfected with Myc-tagged wild-type ROR␥t, the K360R mutant, FLAG-tagged USP17, and HA-tagged ubiquitin. 48 h later, cell lysates were harvested, and immunoprecipitation (IP) was performed with anti-Myc antibodies. Data are representative of more than three independent experiments.
Taken together, these results suggest that lysine 360 is one of the major sites for ROR␥t stabilization, which could be deubiquitinated by USP17.
Knockdown of USP17 Decreases ROR␥t Protein Levels and the Expression of Th17-related Genes in Th17
Cells-To further investigate the mechanism of USP17 by which USP17 regulates Th17 cells, we constructed three specific shRNAs against USP17 to reduce the endogenous expression of USP17 in Th17 cells. Although all three shRNAs targeted USP17, shUSP17-3 had the best knockdown efficacy (Fig. 6A ). We found that the silencing of USP17 in FLAG-ROR␥t-Jurkat cells resulted in a decrease in ROR␥t protein stability (Fig. 6B) . We detected the down-regulation of both endogenous ROR␥t and USP17 at the protein level by immunoblotting in shUSP17 knockdown human primary Th17 cells and assessed relative protein levels by quantification ( Fig. 6C ). Furthermore, we observed the reduction in the expression of Th17-related genes such as IL-17A, IL-17F and IL-23R, which are pivotal for Th17 cell function (Fig. 6D) . These findings support the notion that USP17 is essential for the stabilization of ROR␥t to promote the function of primary Th17 cells.
The USP17 Transcription Level Is Increased Significantly in CD4 ϩ T Cells of Active Systemic Lupus Erythematosus-It has been well established that Th17 may have an essential role in the pathogenesis of systemic lupus erythematosus and lupus nephritis (23) (24) (25) . To test the relevance of USP17 and Th17 cells in SLE, we checked the expression of USP17, ROR␥t, and Th17-type cytokines in CD4 ϩ T cells isolated from the peripheral blood of SLE patients. Healthy donor CD4 ϩ T cells were used as a control. Notably, the up-regulation of USP17, IL-17A, and IL-17F mRNA levels was observed in SLE patients compared with healthy controls (Fig. 7A ). Moreover, significant positive correlations between USP17 and IL-17A (r 2 ϭ 0.5439, p Ͻ 0.05) or IL-17F (r 2 ϭ 0.577, p Ͻ 0.05) were observed in these SLE patients (Fig. 7B ). Additionally, USP17 was increased significantly in active SLE patients (Fig. 7C ). Collectively, these data suggest that USP17 may be involved in the pathogenesis of Th17 cells in SLE patients.
DISCUSSION
Since the discovery of Th17 cells, numerous transcription factors that are involved in the generation of Th17 cells have been described. Among these transcription factors, ROR␥t plays a central role by interacting with other factors to orchestrate the functions and development of Th17 cells.
In parallel with the specific role of ROR␥t in Th17 cells, T-bet, GATA3, and FOXP3 also specify Th1, Th2, and regulatory T cell fates, respectively (26) . Several groups have suggested the important role of ubiquitination in the function of CD4 ϩ T cell subsets. The ubiquitin ligase Stub1, for example, negatively modulates regulatory T cell suppressive activity by promoting the degradation of Foxp3 (27) , whereas the stabilization of Foxp3 by the deubiquitinase USP7 increases the suppressive capacity of regulatory T cells (28) . The E3 ligase Mdm2 (29) and the deubiquitinase USP21 (30) have also been identified as regulators that mediate Th2 cell functions by regulating the stability of GATA3. However, little is known about the regulation of Th17 cells via ubiquitin-mediated modifications of ROR␥t, such as E3 ligases or deubiquitinases. In this work, we reveal a novel link between the deubiquitinase USP17 and ROR␥t that promotes the functions of Th17 cells. We found that USP17 can interact with ROR␥t to promote its stability at Lys-360 via Lys-48-linked deubiquitination. In addition, USP17 increases ROR␥t-dependent Il17a promoter transcriptional activity. In the absence of USP17 in Th17 cells and FLAG-ROR␥t-Jurkat cells, endogenous ROR␥t protein levels are reduced markedly, along with the down-regulation of Th17-related genes. More recently, ROR␥t has also been identified as a key transcription factor for a subset of innate lymphoid cell differentiation (31) . It remains to be determined whether USP17 also plays a role in innate lymphoid cell differentiation and function. On the other hand, substrates may have multiple DUBs for ubiquitination modification. For instance, it has been reported that more than one DUB could stabilize and deubiquitinate tumor suppressor p53, including USP7 (32) and USP10 (33) . It should be interesting to further investigate the other potential DUBs and their roles in stabilizing ROR␥t in future studies.
In addition, we also observed increased USP17 levels in patients with active SLE, suggesting the potential role of USP17 in the pathogenesis of SLE. SLE is a chronic autoimmune disease with no currently known cure. Its pathogenic mechanism remains unclear and it has complex clinical symptoms. Our findings may provide a new direction for the pathogenesis of SLE.
Therefore, we propose the following working model for USP17 and ROR␥t: USP17 is induced under certain inflammatory cytokines, such as IL-6 (18), leading to the stable expression of ROR␥t. Stable expression of ROR␥t then promotes the function of Th17 cells by increasing ROR␥t-dependent transcriptional activities (Fig. 7D) . The signaling pathway for the induction of USP17 and ROR␥t needs to be investigated further in vivo. According to our data from SLE patient CD4 ϩ T cells, the presence of USP17 may be used as a biomarker for SLE to assess patient disease activity. Moreover, our data suggest that the enzymatic activity of USP17 could be an attractive drug target for developing future therapeutic intervention strategies. FIGURE 7 . USP17 is increased significantly in CD4 ؉ T cells of active systemic lupus erythematosus. A, CD4 ϩ T cells were isolated from the peripheral blood of SLE patients and healthy controls. IL-17A, IL-17F, ROR␥t, and USP17 mRNA levels were detected via quantitative PCR analysis. B, correlation between USP17 and IL-17A or IL-17F. C, comparison of USP17 between the inactive SLE group, the active SLE group, and healthy donors. NS, not significant. D, proposed working model in which USP17 stabilizes ROR␥t by deubiquitination. Ub, ubiquitin. Data are representative of more than three independent experiments. Error bars show mean Ϯ S.D.
